Publications by authors named "Jennifer Midiani Gonella"
Background: Antiplatelet drugs, such as clopidogrel, ticagrelor, prasugrel, and acetylsalicylic acid, may be associated with a risk of adverse events (AEs). Vanessa's Law was enacted to strengthen regulations to protect Canadians from drug-related side effects (with mandatory reporting of serious adverse events [SAEs]).
Objective: To determine whether Vanessa's Law has led to an increase in SAE reporting among antiplatelet users.
Polypharmacy and high-alert medications in patients with nasally placed feeding tube on admission and at hospital discharge: Multicenter cross-sectional study.
Explor Res Clin Soc Pharm
September 2024
Article Synopsis
- - A study examined the prescription patterns of medications for patients with nasally placed feeding tubes (NPFT) and found that 92% were on polypharmacy (multiple medications) upon admission, decreasing slightly to 84.7% at discharge.
- - High-alert medications (those that pose a significant risk if used inappropriately) made up over 17% of all prescriptions, with no significant change in their usage between admission and discharge.
- - The study highlights the need for coordinated care strategies to manage the medication risks associated with NPFT patients, particularly given their complex health conditions.
Background: The core motive of pharmacovigilance is the detection and prevention of adverse drug reactions (ADRs), to improve the risk-benefit balance of the drug. However, the causality assessment of ADRs remains a major challenge among clinicians, and none of the available tools of causality assessment used for assessing ADRs have been universally accepted.
Objective: To provide an up-to-date overview of the different causality assessment tools.
Background: Patients with chronic or acute/postoperative pain frequently use opioids. However, opioids may cause considerable adverse reactions (ARs), such as respiratory depression, which could be lethal. Unfortunately, only 5% of drug-related ARs (including those to opioids) are reported to health authorities.
View Article and Find Full Text PDFBackground: Previous systematic reviews (2008; 2016) concluded similarity in outcomes between brand-name and generic drugs in cardiology, but they included ≥ 50% comparative bioavailability studies, not designed or powered to detect a difference in efficacy or safety between drug types. We aimed to summarise best-evidence regarding the effectiveness and safety of generic versus brand-name drugs used in cardiology.
Methods: For this systematic review of the literature, scientific databases (MEDLINE and EMBASE) were searched from January 1984 to October 2018.